{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:07:51Z","timestamp":1777860471906,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["0053008"],"award-info":[{"award-number":["0053008"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["13OC0003898"],"award-info":[{"award-number":["13OC0003898"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.diabres.2022.109943","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T11:37:47Z","timestamp":1654688267000},"page":"109943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Association between plasma apolipoprotein M and cardiac autonomic neuropathy in type 1 diabetes"],"prefix":"10.1016","volume":"189","author":[{"given":"Mostafa","family":"Safi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Borup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Stevns Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Thorsten Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Christoffersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2022.109943_b0005","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/dc09-1294","article-title":"Cardiac autonomic neuropathy in diabetes: a clinical perspective","volume":"33","author":"Pop-Busui","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2022.109943_b0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2261-6-19","article-title":"Circadian rhythm of the autonomic nervous system in insulin resistant subjects with normoglycemia, impaired fasting glycemia, impaired glucose tolerance, type 2 diabetes mellitus","volume":"6","author":"Perciaccante","year":"2006","journal-title":"BMC Cardiovasc Disord"},{"issue":"8","key":"10.1016\/j.diabres.2022.109943_b0015","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1464-5491.2007.02163.x","article-title":"The relationship of heart rate and heart rate variability to non-diabetic fasting glucose levels and the metabolic syndrome: the Cardiovascular Health Study","volume":"24","author":"Stein","year":"2007","journal-title":"Diabet Med"},{"issue":"4","key":"10.1016\/j.diabres.2022.109943_b0020","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s001250050924","article-title":"The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT)","volume":"41","author":"Not Available","year":"1998","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.diabres.2022.109943_b0025","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/dmrr.1239","article-title":"Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management","volume":"27","author":"Spallone","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.diabres.2022.109943_b0030","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11892-014-0528-7","article-title":"Glucose control and diabetic neuropathy: lessons from recent large clinical trials","volume":"14","author":"Ang","year":"2014","journal-title":"Curr Diab Rep"},{"issue":"1","key":"10.1016\/j.diabres.2022.109943_b0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2337\/dc13-2114","article-title":"Neuropathy and related findings in the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study","volume":"37","author":"Martin","year":"2014","journal-title":"Diabetes Care"},{"issue":"22","key":"10.1016\/j.diabres.2022.109943_b0040","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1161\/CIRCULATIONAHA.108.837369","article-title":"Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications study (DCCT\/EDIC)","volume":"119","author":"Pop-Busui","year":"2009","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.diabres.2022.109943_b0045","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.2337\/diacare.27.12.2942","article-title":"Autonomic symptoms and diabetic neuropathy: a population-based study","volume":"27","author":"Low","year":"2004","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.diabres.2022.109943_b0050","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1089\/dia.2018.0249","article-title":"Prevalence of Diabetic Neuropathy in Young Adults with Type 1 Diabetes and the Association with Insulin Pump Therapy","volume":"20","author":"Christensen","year":"2018","journal-title":"Diabetes Technol Ther"},{"issue":"5","key":"10.1016\/j.diabres.2022.109943_b0055","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1007\/s00125-015-3534-7","article-title":"Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: the KORA S4 survey","volume":"58","author":"Ziegler","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2022.109943_b0060","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2337\/diacare.29.04.06.dc05-1729","article-title":"The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program","volume":"29","author":"Carnethon","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2022.109943_b0065","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3389\/fnins.2018.00591","article-title":"Cardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events","volume":"12","author":"Vinik","year":"2018","journal-title":"Front Neurosci"},{"issue":"7","key":"10.1016\/j.diabres.2022.109943_b0070","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/dmrr.1224","article-title":"Methods of investigation for cardiac autonomic dysfunction in human research studies","volume":"27","author":"Bernardi","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"10.1016\/j.diabres.2022.109943_b0075","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.tcb.2011.09.003","article-title":"Sphingosine-1-phosphate signaling and its role in disease","volume":"22","author":"Maceyka","year":"2012","journal-title":"Trends Cell Biol"},{"issue":"3","key":"10.1016\/j.diabres.2022.109943_b0080","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.cell.2008.08.040","article-title":"Anatomical profiling of G protein-coupled receptor expression","volume":"135","author":"Regard","year":"2008","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.diabres.2022.109943_b0085","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bcp.12129","article-title":"Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study","volume":"76","author":"Brossard","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.diabres.2022.109943_b0090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pharmthera.2007.04.006","article-title":"Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology","volume":"115","author":"Brinkmann","year":"2007","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.diabres.2022.109943_b0095","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/jcph.244","article-title":"Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration","volume":"54","author":"Brossard","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.diabres.2022.109943_b0100","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/cpt.877","article-title":"Modeling Tolerance Development for the Effect on Heart Rate of the Selective S1P1 Receptor Modulator Ponesimod","volume":"103","author":"Lott","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.diabres.2022.109943_b0105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.msard.2017.10.020","article-title":"Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis","volume":"19","author":"Akbulak","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.diabres.2022.109943_b0110","doi-asserted-by":"crossref","first-page":"12768","DOI":"10.1038\/s41598-020-69566-y","article-title":"Plasma sphingosine 1-phosphate concentrations and cardiovascular autonomic neuropathy in individuals with type 2 diabetes","volume":"10","author":"Chung","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.diabres.2022.109943_b0115","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbalip.2018.12.001","article-title":"Diurnal regulation of sphingolipids in blood","volume":"1864","author":"Brunkhorst","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"23","key":"10.1016\/j.diabres.2022.109943_b0120","doi-asserted-by":"crossref","first-page":"9613","DOI":"10.1073\/pnas.1103187108","article-title":"Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M","volume":"108","author":"Christoffersen","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.diabres.2022.109943_b0125","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1194\/jlr.R700011-JLR200","article-title":"HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects","volume":"48","author":"Argraves","year":"2007","journal-title":"J Lipid Res"},{"issue":"6","key":"10.1016\/j.diabres.2022.109943_b0130","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1161\/ATVBAHA.117.309275","article-title":"A Shift in ApoM\/S1P Between HDL-Particles in Women With Type 1 Diabetes Mellitus Is Associated With Impaired Anti-Inflammatory Effects of the ApoM\/S1P Complex","volume":"37","author":"Frej","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.diabres.2022.109943_b0135","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1194\/jlr.M700113-JLR200","article-title":"An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma","volume":"48","author":"Axler","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.diabres.2022.109943_b0140","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s00125-014-3164-5","article-title":"Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study","volume":"57","author":"Jensen","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2022.109943_b0145","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jcmg.2014.12.020","article-title":"Global longitudinal strain is not impaired in type 1 diabetes patients without albuminuria: the Thousand & 1 study","volume":"8","author":"Jensen","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.diabres.2022.109943_b0150","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/1479164116637310","article-title":"Early myocardial impairment in type 1 diabetes patients without known heart disease assessed with tissue Doppler echocardiography: The Thousand & 1 study","volume":"13","author":"Jensen","year":"2016","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.diabres.2022.109943_b0155","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1007\/s00125-019-05009-2","article-title":"Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 diabetes and without known heart disease: the Thousand & 1 Study","volume":"62","author":"Jensen","year":"2019","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.diabres.2022.109943_b0160","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2337\/db18-1313","article-title":"Cardiac Autonomic Function Is Associated With Myocardial Flow Reserve in Type 1 Diabetes","volume":"68","author":"Zobel","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2022.109943_b0165","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1161\/01.CIR.93.5.1043","volume":"93","year":"1996","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.diabres.2022.109943_b0170","doi-asserted-by":"crossref","first-page":"956","DOI":"10.2337\/diacare.28.4.956","article-title":"Diabetic neuropathies: a statement by the American Diabetes Association","volume":"28","author":"Boulton","year":"2005","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2022.109943_b0175","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/dme.12753","article-title":"The role of serum methylglyoxal on diabetic peripheral and cardiovascular autonomic neuropathy: the ADDITION Denmark study","volume":"32","author":"Hansen","year":"2015","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2022.109943_b0180","unstructured":"Spallone V. Raccomandozioni sull'uso dei test cardiovascolari nella diagnosi di neuropatia autonomica diabetica. 1990."},{"issue":"1","key":"10.1016\/j.diabres.2022.109943_b0185","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2337\/dc16-2042","article-title":"Diabetic Neuropathy: A Position Statement by the American Diabetes Association","volume":"40","author":"Pop-Busui","year":"2017","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.diabres.2022.109943_b0190","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/dme.13777","article-title":"Cardiovascular autonomic neuropathy and bone metabolism in Type 1 diabetes","volume":"35","author":"Hansen","year":"2018","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.diabres.2022.109943_b0195","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1194\/jlr.D055947","article-title":"Protein unfolding allows use of commercial antibodies in an apolipoprotein M sandwich ELISA","volume":"56","author":"Bosteen","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.diabres.2022.109943_b0205","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2337\/diabetes.51.2.514","article-title":"The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes","volume":"51","author":"Pacher","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2022.109943_b0210","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2337\/diacare.26.5.1553","article-title":"Diabetic autonomic neuropathy","volume":"26","author":"Vinik","year":"2003","journal-title":"Diabetes Care"},{"issue":"18","key":"10.1016\/j.diabres.2022.109943_b0215","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.045323","article-title":"Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure","volume":"141","author":"Chirinos","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.diabres.2022.109943_b0220","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/cvr\/cvw004","article-title":"Sphingosine-1-phosphate reduces ischaemia-reperfusion injury by phosphorylating the gap junction protein Connexin43","volume":"109","author":"Morel","year":"2016","journal-title":"Cardiovasc Res"},{"issue":"8","key":"10.1016\/j.diabres.2022.109943_b0225","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.bbamem.2011.07.039","article-title":"Functional consequences of abnormal Cx43 expression in the heart","volume":"1818","author":"Fontes","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"10.1016\/j.diabres.2022.109943_b0230","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/01.RES.0000144125.61927.1c","article-title":"Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy","volume":"95","author":"Akar","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.diabres.2022.109943_b0235","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.665393","article-title":"Apolipoprotein M-A Marker or an Active Player in Type II Diabetes?","volume":"12","author":"Christoffersen","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"10.1016\/j.diabres.2022.109943_b0240","doi-asserted-by":"crossref","first-page":"158969","DOI":"10.1016\/j.bbalip.2021.158969","article-title":"Increased plasma apoM levels impair triglyceride turnover in mice","volume":"1866","author":"Hajny","year":"2021","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"1","key":"10.1016\/j.diabres.2022.109943_b0245","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.atherosclerosis.2011.11.031","article-title":"Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL","volume":"221","author":"Els\u00f8e","year":"2012","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.diabres.2022.109943_b0250","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1194\/jlr.M700103-JLR200","article-title":"Hydrophobic ligand binding properties of the human lipocalin apolipoprotein M","volume":"48","author":"Ahnstr\u00f6m","year":"2007","journal-title":"J Lipid Res"},{"issue":"9","key":"10.1016\/j.diabres.2022.109943_b0255","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40265-021-01528-8","article-title":"Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis","volume":"81","author":"P\u00e9rez-Jeldres","year":"2021","journal-title":"Drugs"},{"issue":"492","key":"10.1016\/j.diabres.2022.109943_b0260","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aal2722","article-title":"An engineered S1P chaperone attenuates hypertension and ischemic injury","volume":"10","author":"Swendeman","year":"2017","journal-title":"Sci Signal"},{"key":"10.1016\/j.diabres.2022.109943_b0265","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.ihj.2018.06.007","article-title":"Co-Existence of hypertension worsens post-exercise cardiac autonomic recovery in type 2 diabetes","volume":"70","author":"Verma","year":"2018","journal-title":"Indian Heart J"},{"key":"10.1016\/j.diabres.2022.109943_b0270","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ekir.2017.03.002","article-title":"Cardiac Autonomic Neuropathy Predicts All-Cause and Cardiovascular Mortality in Patients With End-Stage Renal Failure: A 5-Year Prospective Study","volume":"2","author":"Doulgerakis","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.diabres.2022.109943_b0275","doi-asserted-by":"crossref","DOI":"10.1186\/1758-5996-6-82","article-title":"Association between Brachial-Ankle pulse wave velocity and cardiac autonomic neuropathy in type 2 diabetes","volume":"6","author":"Wu","year":"2014","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.diabres.2022.109943_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/5704713","article-title":"Leukotriene Pathway Activation Associates with Poor Glycemic Control and with Cardiovascular Autonomic Neuropathy in Type 1 Diabetes","volume":"2020","author":"Santos-Bezerra","year":"2020","journal-title":"Mediators Inflamm"},{"issue":"2","key":"10.1016\/j.diabres.2022.109943_b0285","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40200-019-00467-2","article-title":"Identification and performance of multiple clinical and laboratorial risk factors for diagnosis of cardiac autonomic neuropathy in type 1 diabetes patients","volume":"18","author":"Riguetto","year":"2019","journal-title":"J Diabetes Metab Disord"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722007574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722007574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:52:21Z","timestamp":1777510341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822722007574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":56,"alternative-id":["S0168822722007574"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2022.109943","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between plasma apolipoprotein M and cardiac autonomic neuropathy in type 1 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2022.109943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109943"}}